<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81638">
  <stage>Registered</stage>
  <submitdate>10/10/2006</submitdate>
  <approvaldate>23/01/2007</approvaldate>
  <actrnumber>ACTRN12607000071426</actrnumber>
  <trial_identification>
    <studytitle>TARCEVA: A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.</studytitle>
    <scientifictitle>A randomised, multicentre, phase III study of Erlotinib versus observation in patients
with no evidence of disease progression after first line, platinum-based chemotherapy
for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or
fallopian tube cancer to improve progression-free survival.</scientifictitle>
    <utrn />
    <trialacronym>EORTC TARCEVA 55041</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00263822</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ovarian epithelial, primary peritoneal, or fallopian tube cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1)Treatment Arm: Erlotinib 150 mg orally, administered on a daily basis, up to 2 years</interventions>
    <comparator>2)Observation Arm: observation only (standard of care) up to 2 years.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>Measured as clinically indicated during treatment/observation or follow-up, and at the end of treatment/observation, until recurrence.   Abdominal and pelvic Computed tomography (CT) scans and chest X-ray will be performed when clinically indicated, when progression is suspected either clinically or by CA125 monitoring, or at the discretion of the treating physician.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>Measured from randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse event profile</outcome>
      <timepoint>Measured every 3 months during treatment/observation and at follow-up (follow-up at least every 3 months during the first and second year, every 4 months in the 3rd and 4th year, every 6 months the 5th year and thereafter once every year until death)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life (QoL)</outcome>
      <timepoint>Measured pre-treatment and every 3 months during treatment/observation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cutaneous toxicity [rash or acne (papulo-pustular rash)]</outcome>
      <timepoint>Measured every 3 months during treatment/observation and at follow-up (follow-up at least every 3 months during the first and second year, every 4 months in the 3rd and 4th year, every 6 months the 5th year and thereafter once every year until death.)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Histologically confirmed high-risk International Federation of Gynecology and Obstetrics (FIGO) stage I (grade 3, or aneuploid grade 1 or 2, or clear cell), or stage II-IV ovarian epithelial, primary peritoneal, and fallopian tube cancer.2.Complete response (CR) (clinical and/or pathological, i.e., no evidence of disease [NED] status), partial response (PR), or disease stabilization (SD) after first line therapy3. Eastern Cooperative Oncology Group (ECOG) 0-1. 4. Randomisation within 6 weeks of the end of first line therapy for ovarian cancer (Carboplatin or Cisplatin). 5.Adequate bone marrow, hepatic and renal functions. 6.Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Adenocarcinoma of unknown origin.2.Prior or concurrent treatment with any other investigational agent3.Prior therapy targeting the epidermal growth factor receptor (EGFR)4.Prior allergic reaction to any compound chemically related to the study drug5.Previous (within the last 5 years) or concurrent malignancies6.Known history of brain metastases and/or leptomeningeal disease.7.Gastrointestinal tract disease resulting in an inability to take oral medication or requiring parenteral nutrition or affecting absorption. Active peptic ulcer disease.8.Uncontrolled bowel inflammatory disease (e.g., Crohn´s disease or ulcerative colitis).9.Myocardial infarction within the past 6 months.10.Second- or third-degree heart blocks unless pacemaker implanted.11.Significant dermatological disease.12.Inflammatory changes of the surface of the eye.13.Other significant medical condition, neurological or psychiatric disorder.14.Pregnant or lactating women (or potentially fertile women not using adequate contraception).15.Prior radiotherapy.16.Any condition potentially hampering compliance with the study protocol and follow-up schedule.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Centralised web-based randomisation, concealed until interventions are assigned</concealment>
    <sequence>Minimisation technique</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>22/09/2005</anticipatedstartdate>
    <actualstartdate>15/10/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate>19/02/2008</actualenddate>
    <samplesize>830</samplesize>
    <actualsamplesize>855</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>European Organisation for Research and Treatment of Cancer</primarysponsorname>
    <primarysponsoraddress>Avenue E. Mounierlaan 83/11
B-1200 Brussels</primarysponsoraddress>
    <primarysponsorcountry>Belgium</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>European Organisation for Research and Treatment of Cancer</fundingname>
      <fundingaddress>Avenue E. Mounierlaan 83/11
B-1200 Brussels</fundingaddress>
      <fundingcountry>Belgium</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Australia New Zealand Gynaecological Oncology Group (ANZGOG)</sponsorname>
      <sponsoraddress>Locked Bag 77
Camperdown NSW 1450</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>University of Sydney in collaboration with Eastern Organisation for Research and Treatment of Cancer (EORTC)</sponsorname>
      <sponsoraddress>Faculty of Medicine
K25
University of Sydney
NSW 2006</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Roche</sponsorname>
      <sponsoraddress>4-10 Inman Road
Dee Why NSW 2099</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine whether the administration of Erlotinib (maintenance treatment) after first line chemotherapy in patients with ovarian cancer can provide improved outcomes in terms of progression-free survival, compared with the standard approach of observation alone.  Roche only will be supplying the drug.</summary>
    <trialwebsite />
    <publication>Vergote I, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer C, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed N, Curé H, Pujade-Lauraine E. Randomised phase III study of erlotinib versus 1 observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. An EORTC-GCG and Gynecological Cancer Intergroup study. Journal of Clinical Oncology. Published ahead of print on December 23, 2013 as 10.1200/JCO.2013.50.5669</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Central Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/02/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Manning Rural Referral Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/02/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tamworth Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/02/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/02/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/07/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/02/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/12/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/01/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Palmerston North Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/01/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/07/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress>New ethics address. Please modify.</ethicaddress>
      <ethicapprovaldate>22/11/2007</ethicapprovaldate>
      <hrec>New ethics HREC. Please modify.</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Julie Martyn</name>
      <address>Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 95625092</phone>
      <fax>+61 2 95625094</fax>
      <email>julie.martyn@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Christopher Steer</name>
      <address>Border Medical Oncology
Nordsvan Drive
Wodonga VIC 3690</address>
      <phone>+61 2 60553200</phone>
      <fax>+61 2 60567669</fax>
      <email>CSteer@bordermedonc.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lakshmi Waniganayake</name>
      <address>Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 95625391</phone>
      <fax>+61 2 95625094</fax>
      <email>lwaniganayake@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Christopher Steer</name>
      <address>Border Medical Oncology
Nordsvan Dr and Pearce Dr, 
Wodonga VIC 3690</address>
      <phone>(02) 6051 5300</phone>
      <fax />
      <email>Csteer@bordermedonc.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>